ALK Positive

🫁 Important contribution addressing one of the most challenging scenarios in #thoraciconcology: #lungcancer diagnosed during #pregnancy. 🤰 Key takeaways: • Multidisciplinary care is essential 🧑🏽‍⚕️👩‍⚕️👨🏾‍⚕️ • Comprehensive molecular profiling remains critical 🧬 #ALKpositive #EGFR • More prospective data are urgently needed to guide treatment decisions for both mother and fetus 📈 Congratulations to the team on this important work during #WomensHealthMonth and ongoing @YoungLungCancer awareness efforts. @GO2forLungCancr @LUNGevity @ALKpositiveinc @EGFRResisters @IASLC @OncoAlert @ALKpositiveINT @EgfrUk @ASCO @myESMO @lcrf_org @OncodailyLung @NehemiasGuevar5 @Florez_Lab @Florez_Lab @COlazagasti

Thanks to Leif and the whole crew at The Cork 50131 for hosting us! It was a great time learning about Spanish wines and raising money for @ALKPositiveinc!

Join us on May 14 at 1.30pm ET for a conversation on how heritable genetics can drive the next generation of lung cancer research. Register: LCRF.org/together #lungcancer #research #genetics

As #HopeSummit closes, we’re reflecting on a weekend full of connection & hope 🤍 From Dr @DRCamidge’s keynote to the ALK breakout with Dr. David Gerber, it was powerful to come together—patients, care partners, advocates, clinicians. We leave energised to keep sharing hope 💙

Join us this Sunday, May 3 at 7pm ET: ALKtALK with Timothy Burns, MD, PhD, & Joshua Palmer, MD (OSUCCC – James). ALK-positive lung cancer: brain progression raises urgent questions—stay on TKI, radiate, surgery, or leptomeningeal disease? Live Q&A Join: alkpositive.org/living-with-al…

🎉 A highlight from #AACR26 — our Executive & Medical Director, Dr. Ken Culver, had the honor of meeting Dr. Alice Tzeng, the inaugural recipient of the AACR-ALK Positive Lung Cancer Research Fellowship! #ALKPositive #LungCancer #CancerResearch #AACR26 #PatientAdvocacy

Findings from surgery after systemic tx in NSCLC with pleural mets: 📊 Imaging predicted pleural response, offering needed criteria in a space where clear benchmarks have been lacking 📈 Most pts (70.8%) had no residual pleural disease at surgery 🔗 jtcvsopen.org/article/S2666-…

The replay from our latest ALKtALK is live! 🎬 Dr. Alexander Spira joined us to discuss two clinical trials for ALK+ patients, TRI-611 and Gilteritinib, and what they could mean for the future of ALK+ care. ▶️ Watch now: youtube.com/watch?v=0DFJiw… #ALKpositive #ClinicalTrials

🫁Dirozalkib yielded promising efficacy among patients with ALK-positive NSCLC. Data from a phase 2 study presented at #AACR26 showed activity with the novel ALK inhibitor even among those with active brain metastases. #lcsm | @AACR

Personalized medicine is the future for ALK+ #LungCancer and data science is how we get there. Exciting work from our collaborators at @UTMDAnderson on digital twins using #AI to model patient-specific outcomes and guide treatment decisions pointing to a more precise, individualized approach to care. MS.BC02.01 |Ballroom 20 | 3.05pm

This Sunday, Mandy takes on the London Marathon — running for those who can’t. Every step is helping us fund research at the The Institute of Cancer Research to understand and overcome treatment resistance. Watch her story 🎥 + read more 👉 oncogeneresearch.org/icr-festival-t… #LCSM

How much do you know about clinical trials? From placebos to safety to eligibility, there are a lot of myths out there. Take our True or False Clinical Trials Quiz and see how you do! 🔬 alkpositive.org/blog/true-or-f… #LearnAboutALKPositive #ALKPositive #ClinicalTrials #ALKResearch

After discontinuing the NVL-655 trial due to liver toxicity, ALK-positive patient and ALK Positive board member, Jeff Sturm, accessed the investigational drug zidesamtinib through a single-patient IND. Read his experience here: alkpositive.org/blog/patient-p… #LearnAboutALKPositive

Join us at the 2026 @ASCO Annual Meeting in Chicago where we'll present clinical updates from our #ALK+ #NSCLC and #ROS1+ programs. Learn more: investors.nuvalent.com/2026-04-21-Nuv… #ASCO26

We’re excited to be here in Vienna this week for the @LungCancerEu 2026 Conference with the 46+ members and attendees 💙 Because advancing outcomes in lung cancer takes all of us — sharing, learning, and working together across borders. #LCSM

Learn About ALK+: Guardant360 Liquid Biopsy This blood-based test detects tiny amounts of tumor DNA, helping guide treatment when tissue biopsies aren’t feasible. Learn more: alkpositive.org/blog/understan… #ALKPositive #PrecisionMedicine #LiquidBiopsy

🎥 REPLAY NOW AVAILABLE | ALKtALK with Dr. Jonathan Riess & Johanna Han The replay is ready for you. 👇 ▶️ youtu.be/ZExawDp9tAE?si… Dr. Riess and Johanna Han break down single-patient INDs, eligibility, timelines, and emerging therapies like ivonescimab for ALK+ patients.

🔬 ALK Positive is at #AACR26 in San Diego! Our Executive & Medical Director Dr. Ken Culver and Medical Team Project Manager Sadia Yaakov are on the ground advocating for the ALK-positive community. If you're attending, come say hello — they'd love to connect! 👋

Research Update: TKI + Chemo A multi-center study in ALK+ NSCLC found continuing ALK TKI with platinum/pemetrexed after progression may improve survival and lower brain progression risk—supporting current clinical practice. Learn more: alkpositive.org/blog/continuin… #ALKPositive

At the Genentech Experience Exchange for Patient Advocates this week in San Francisco, Ken Culver, our Executive and Medical Director, joined more than 120 organizations coming together to support the cancer community. #ALKPositive #StrongerTogether #PatientAdvocacy